This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Cidara Therapeutics, Inc.
Drug Names(s): CD 201, CD-201
Description: CD201 is a novel, bispecific antimicrobial immunotherapy from Cidara's proprietary immunotherapy discovery platform, Cloudbreak. The Cloudbreak bifunctional small molecule platform utilizes a targeting moiety (TM) that binds to the pathogen and is conjugated to an effector moiety (EM) that attracts and activates immune cells, directing them to the site of infection and priming them for killing.
Additional information available to subscribers only: